Article
TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Oct 2022
Thiel Kristina W, Devor Eric J, Filiaci Virginia L, Mutch David, Moxley Katherine, Alvarez Secord Angeles, Tewari Krishnansu S, McDonald Megan E, Mathews Cara, Cosgrove Casey, Dewdney Summer, Aghajanian Carol, Samuelson Megan I, Lankes Heather A, Soslow Robert A, Leslie Kimberly K
Abstract excerpt
PURPOSE: The status of p53 in a tumor can be inferred by next-generation sequencing (NGS) or by immunohistochemistry (IHC). We examined the association between p53 IHC and sequence and whether p53 IHC alone, or integrated with TP53 NGS, predicts the outcome. METHODS: From GOG-86P, a randomized phase II study of chemotherapy combined with either bevacizumab or temsirolimus in advanced endometrial cancer, 213 cases...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.